133 related articles for article (PubMed ID: 15920862)
1. Partial dopamine agonists in schizophrenia.
Launer M
Hosp Med; 2005 May; 66(5):300-3. PubMed ID: 15920862
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
Crismon ML; DeLeon A; Miller AL
Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
[No Abstract] [Full Text] [Related]
4. Aripiprazole as a dopamine partial agonist: positive and negative effects.
Glick ID; Duggal V; Hodulik C
J Clin Psychopharmacol; 2006 Feb; 26(1):101-3. PubMed ID: 16415723
[No Abstract] [Full Text] [Related]
5. Aripiprazole (Abilify) for schizophrenia.
Med Lett Drugs Ther; 2003 Feb; 45(1150):15-6. PubMed ID: 12592215
[No Abstract] [Full Text] [Related]
6. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
[No Abstract] [Full Text] [Related]
7. Worsening of psychosis in a 30 year old man with undifferentiated schizophrenia.
Ahuja N; Lloyd AJ
Ann Clin Psychiatry; 2008; 20(2):113-4. PubMed ID: 18568584
[No Abstract] [Full Text] [Related]
8. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Keck PE; McElroy SL
Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
[TBL] [Abstract][Full Text] [Related]
9. Reversal of symptomatic hyperprolactinemia by aripiprazole.
Wahl R; Ostroff R
Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
[No Abstract] [Full Text] [Related]
10. Aripiprazole in the treatment of Alzheimer's disease.
De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
[TBL] [Abstract][Full Text] [Related]
11. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Freeman B; Levy W; Gorman JM
J Psychiatr Pract; 2007 Mar; 13(2):120-4. PubMed ID: 17414690
[No Abstract] [Full Text] [Related]
12. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.
Yeh YW
Clin Neuropharmacol; 2011; 34(4):135-6. PubMed ID: 21768798
[TBL] [Abstract][Full Text] [Related]
13. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents.
Prescrire Int; 2009 Dec; 18(104):251. PubMed ID: 20025091
[No Abstract] [Full Text] [Related]
15. Do dopamine partial agonists have partial efficacy as antipsychotics?
Stahl SM
CNS Spectr; 2008 Apr; 13(4):279-82. PubMed ID: 18408646
[No Abstract] [Full Text] [Related]
16. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
Shirley M; Perry CM
Drugs; 2014 Jul; 74(10):1097-110. PubMed ID: 24969315
[TBL] [Abstract][Full Text] [Related]
17. Partial agonists in schizophrenia.
Cousins DA; Young AH
Br J Psychiatry; 2005 Apr; 186():354. PubMed ID: 15802697
[No Abstract] [Full Text] [Related]
18. Partial agonism and schizophrenia.
Bolonna AA; Kerwin RW
Br J Psychiatry; 2005 Jan; 186():7-10. PubMed ID: 15630117
[No Abstract] [Full Text] [Related]
19. Partial agonists and suicide: the role of the mental health nurse.
Jones M; Gray R
J Psychiatr Ment Health Nurs; 2008 Apr; 15(3):253-9. PubMed ID: 18307655
[No Abstract] [Full Text] [Related]
20. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
